Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MLNR | O43193 | 2/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28856183 | 0.82 | SIGMAR1 (0.34) | MEN1KMT2AMLNRSIGMAR1CHRM5 | |
| SCHEMBL28199273 | 0.79 | SIGMAR1 (0.36) | MLNRSIGMAR1CHRM5CHRM3 | |
| SCHEMBL27618554 | 0.77 | SIGMAR1 (0.46) | SIGMAR1 | |
| SCHEMBL28199286 | 0.77 | POLB (0.41) | MEN1KMT2ASIGMAR1 | |
| SCHEMBL6622116 | 0.72 | KMT2A (0.48) | MEN1KMT2ASIGMAR1 | |
| SCHEMBL391242 | 0.71 | MEN1 (0.40) | MEN1KMT2ASIGMAR1CHRM5CHRM3 | |
| SCHEMBL2009423 | 0.70 | SIGMAR1 (0.61) | MEN1KMT2AMLNRSIGMAR1CHRM5 | |
| Hydrochloric Acid SCHEMBL2010274 | 0.69 | SIGMAR1 (0.60) | MEN1KMT2AMLNRSIGMAR1CHRM5 | |
| SCHEMBL28199271 | 0.69 | CA2 (0.38) | KMT2ASIGMAR1CHRM5CHRM3 | |
| SCHEMBL296666 | 0.68 | SLC6A4 (0.44) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1861376-A1 | CIS-2,4,5-TRIARYL-IMIDAZOLINES AND THEIR USE AS ANTI-CANCER MEDICAMENTS | F. Hoffmann-Roche AG (CH) | 2007-12-05 | — | — | EP | disclosed |
| WO-2006097261-A1 | CIS-2,4,5-TRIARYL-IMIDAZOLINES AND THEIR USE AS ANTI-CANCER MEDICAMENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-09-21 | — | — | WO | disclosed |